Bristol Myers Squibb (NYSE:BMY) Hits New 1-Year High – Should You Buy?

Bristol Myers Squibb Company (NYSE:BMY)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $68.19 and last traded at $68.2230, with a volume of 1320328 shares changing hands. The stock had previously closed at $66.05.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a collaboration with Chai Discovery to use artificial intelligence for antibody discovery. The partnership could improve the speed and efficiency of developing new therapies, although financial terms and the near-term earnings impact were not disclosed. Chai Discovery collaboration with Bristol Myers Squibb
• Positive Sentiment: An update on the Phase 1 study of navlimetostat indicates continued progress in Bristol Myers Squibb’s early-stage pipeline. The program remains experimental, so any commercial benefit is still distant and uncertain. Bristol Myers Squibb navlimetostat study update
• Positive Sentiment: Hematogenix said its minimal residual disease assay supported the FDA’s accelerated approval of Bristol Myers Squibb’s ZENBEXUS™, described as the first approved CELMoD therapy for multiple myeloma. The approval could expand the company’s oncology opportunity, though accelerated approvals typically require confirmatory evidence. Hematogenix assay and ZENBEXUS approval
• Positive Sentiment: Unusually heavy call-option activity, with 55,757 calls purchased—more than double the average volume—signals increased speculative interest in BMY. Options activity is not confirmation of a sustained rally and can increase volatility.
• Positive Sentiment: Analyst coverage continues to characterize BMY as an attractive value stock, supported by its relatively low valuation and income potential. A separate comparison also frames Bristol Myers Squibb as a potential bargain versus AstraZeneca, though these are opinion-based assessments. Zacks BMY value-stock analysis
• Neutral Sentiment: Articles discussing a covered-call strategy emphasize income generation rather than a bullish outlook for capital appreciation. The strategy may appeal to yield-focused investors but can limit upside if the shares rise sharply. Bristol Myers Squibb options income strategy
• Neutral Sentiment: A report on Aktis Oncology, which has attracted interest from Bristol Myers Squibb and other large pharmaceutical companies, highlights potential future deal activity but does not announce a transaction or create an immediate financial impact for BMY. Pharmaceutical interest in Aktis Oncology

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on BMY shares. Royal Bank Of Canada increased their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Piper Sandler began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating for the company. Raymond James Financial initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Jefferies Financial Group downgraded shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Price Performance

The firm has a market cap of $133.88 billion, a PE ratio of 14.44, a price-to-earnings-growth ratio of 0.18 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a 50-day simple moving average of $60.35 and a 200 day simple moving average of $59.31.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the prior year, the firm earned $1.46 EPS. The company’s revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Institutional Trading of Bristol Myers Squibb

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after acquiring an additional 2,743,759 shares during the last quarter. BlackRock Inc. increased its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp raised its holdings in Bristol Myers Squibb by 1.4% in the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after buying an additional 1,385,206 shares during the last quarter. Geode Capital Management LLC lifted its position in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at $1,947,272,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.